CD39

CD39

CD39 詳細

Molecule Name
Ectonucleoside triphosphate diphosphohydrolase 1
分子の別称
CD39,ENTPD1,NTPDase 1,Entpd1,Ecto-ATPDase 1,Ecto-ATPase 1
Drug Development Progress
治験薬の数11
市販薬剤の数0
研究&開発段階Phase 2 Clinical
ターゲットの別称
CD39 Antigen,CD39,EC 3.6.1.5,NTPDase-1,NTPDase 1,ATPDase,SPG64,EC:3.6.1.5,Ecto-ATPase 1,Lymphoid cell activation antigen,ENTPD1,Ectonucleoside Triphosphate Diphosphohydrolase 1,Ecto-ATPDase 1,Ecto-Apyrase,Ecto-ATP diphosphohydrolase 1,EC 3.6.1
バックグランド
CD39 is also known as Ectonucleoside triphosphate diphosphohydrolase 1, ENTPD1, NTPDase 1, Ecto-ATPDase 1, in the nervous system, could hydrolyze ATP and other nucleotides to regulate purinergic neurotransmission. Could also be implicated in the prevention of platelet aggregation by hydrolyzing platelet-activating ADP to AMP. Hydrolyzes ATP and ADP equally well. NTPDase-1 was originally described as CD39, a B lymphocyte cell surface marker, but it is also present on the surface of natural killer cells, T cells, and some endothelial cells.Regulatory T cells(Tregs) mediate immunosuppression through multiple, non-redundant, cell-contact dependent and independent mechanisms, a growing body of evidence suggests an important role for the CD39-CD73-adenosine pathway. CD39 ectonucleotidase is the rate-limiting enzyme of a cascade leading to the generation of suppressive adenosine that alters CD4 and CD8 T cell and natural killer cell antitumor activities.

CD39 製品リスト

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
TTX-030TTX-030Phase 2 ClinicalAdimab LLC
Lymphoma; Pancreatic Neoplasms; Solid tumours
詳細
IPH-5201IPH-5201Phase 2 ClinicalInserm, Orega Biotech
Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Solid tumours
詳細
JS-019JS-019Phase 2 ClinicalBeijing Enrini Biotechnology Co Ltd
Eosinophilia; Lymphoma; Solid tumours
詳細
ES-014ES-014Phase 2 ClinicalElpiscience (Shanghai) Biopharma Ltd
Neoplasms; Solid tumours
詳細
PerenostobartSRF-617Phase 1 ClinicalSurface Oncology Inc
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours
詳細
HB-0046HB0046; HB-0046Phase 1 ClinicalHuaBo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd
Solid tumours
詳細
PUR-001PUR-001Phase 1 ClinicalPurinomia Biotech Inc
Solid tumours
詳細
AB-598AB598Phase 1 ClinicalArcus Biosciences Inc
Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Neoplasms; Neoplasms; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms
詳細
AGX-148AGX-148; AGX148Phase 1 ClinicalAgonOx Inc
Colorectal Neoplasms; Genital Neoplasms, Female; Lung Neoplasms; Melanoma; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Urogenital Neoplasms
詳細
EurestobartES-002023Phase 1 ClinicalElpiscience (Shanghai) Biopharma Ltd
Solid tumours
詳細
ES-002ES-002Phase 1 ClinicalElpiscience (Shanghai) Biopharma Ltd
Neoplasms; Solid tumours
詳細